Immuno-Oncology

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

A group of doctors and other healthcare industry professionals have set out to develop a more efficient tool for assessing the true value of immuno-oncology drugs.

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

John Hunter, PhD, and Maya Kotturi, PhD, answer key questions about TIGIT as a target for anticancer therapy and the current development of TIGIT-targeting drugs.

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

As researchers continue to identify a growing number of immune checkpoints as targets for anticancer therapy, the recently discovered TIGIT pathway is emerging as a promising new avenue for exploration.

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.